Global Epidermal Growth Factor Receptor Inhibitor Market 2021 Analysis May Set New Growth Story, Forecast to 2027
The global epidermal growth factor receptor inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are accelerating the growth of the global epidermal growth factor receptor inhibitor market include growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advanced-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering a better safety profile to the patients.
Epidermal growth factor
receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s
activity, a protein found on the surface of some normal cells, by binding to
its certain part. EGFR or epidermal growth factor receptor causes cells to
divide upon binding to it by signalling pathways that control cell division and
survival, leading to the growth of normal cells. Certain mutations in EGFR are
known to be vulnerable and can lead to the growth of cancer cells.
To Request a Sample of our Report on Global Epidermal
Growth Factor Receptor Inhibitor Market: https://www.omrglobal.com/request-sample/epidermal-growth-factor-receptor-inhibitor-market
The global epidermal growth factor receptor inhibitor market analysis
includes some of the key market players such as Amgen Inc., AstraZeneca, Eli
Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others. To
maintain a strong position in the market, these market players are adopting
various strategic moves, such as product launches, partnerships,
collaborations, and mergers and acquisitions. For instance, in April 2021,
Takeda announces US FDA grants priority review for a new drug application for
Mobocertinib (TAK-788) as a treatment for EGFR Exon20 Insertion+ metastatic
non-small cell lung cancer.
Market Coverage
·
The market
number available for – 2020-2027
·
Base year-
2020
·
Forecast
period- 2021-2027
·
Segment
Covered
·
Regions
Covered- Globally
·
Competitive
Landscape: Amgen Inc., AstraZeneca, Eli Lilly and Company, F.
Hoffmann-La Roche Ltd., and Novartis AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Epidermal Growth Factor Receptor Inhibitor Market is
Available at: https://www.omrglobal.com/industry-reports/epidermal-growth-factor-receptor-inhibitor-market
Global Epidermal Growth Factor Receptor Inhibitor Market by Segment
By Type
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others
By Application
• Hospital
• Research Institutes and
Institutions
• Clinic
• Other
Global Epidermal Growth Factor Receptor Inhibitor Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment